Auto CAR-T

PreclinicalCell therapy

HHebei Senlang Biotechnology Inc., Ltd.

Auto CAR-T is one of 120 biologic programs targeting Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Relapsed/refractoryUnknown status

Clinical TrialUnknown status

LymphomaPreclinical

Active, not recruiting

Relapsed/refractoryPreclinical

Unknown status

Clinical TrialPreclinical

Unknown status

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Cabenuva

GSK

Preclinical

1 3

Norvir

AbbVie

Preclinical

1 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma2 trials

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04666168·200 enrolled

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04665063·20 enrolled

Relapsed/Refractory1 trial

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04665076·60 enrolled

Clinical Trial1 trial

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04610125·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Auto CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Auto CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Auto CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hebei Senlang Biotechnology Inc., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: HHebei Senlang Biotechnology Inc., Ltd.

Auto CAR-T

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma2 trials

Relapsed/Refractory1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News